Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Crispr Therapeutics AG (CRSP) Stock Price & Analysis
7,948 Followers
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.55 - $91.10
Previous Close$57.92
Volume867.11K
Average Volume (3M)1.34M
Market Cap
$4.92B
Enterprise Value$3.05B
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$234.93M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Jul 29, 2024EPS Estimate
-$1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding84,918,093
10 Day Avg. Volume1,715,445
30 Day Avg. Volume1,342,757
Standard Deviation0.20
R-Squared0.22
Alpha0.00301
Financial Highlights & Ratios
Price to Book (P/B)2.54
Price to Sales (P/S)12.91
Price to Cash Flow (P/CF)-12.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.26
Enterprise Value/Gross Profit12.70
Enterprise Value/Ebitda-18.10
Forecast
1Y Price Target
$75.13Price Target Upside29.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Crispr Therapeutics AG News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
Bulls Say, Bears Say
Bulls Say
Commercial LaunchCasgevy’s launch is off to a strong start and management is making the right investments to continue its first-in-class and best-in-class platform.
Market PotentialThe opportunity in the Middle East for CASGEVY is a significant one that is underappreciated by investors.
Operational EfficiencyCRISPR expects to file one to two new INDs a year, but importantly, management expects to keep spend flat for the next two years, which speaks to its cost discipline.
Bears Say
Financial PerformanceNet loss per share was higher than consensus, indicating worse than expected financial results.
Market PotentialThe approval of Casgevy is a significant scientific milestone, but it is not expected to be used broadly enough to support the elevated valuation.
ValuationShares appear overvalued based on the Casgevy launch, which may not generate sufficient revenue to justify the current stock price.
---
Ownership Overview
23.59% Insiders
17.93% Mutual Funds
30.01% Other Institutional Investors
28.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $37.55 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Jul 29, 2024 which is in 2 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on May 08, 2024. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.361 by -$0.069.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$1.43.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 84,918,090 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.361. Following the earnings report the stock price went up 0.488%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 556M.
---
Crispr Therapeutics AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.13 (29.71% Upside)
$75.13 (29.71% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 98%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 271.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.11%
12-Months-Change
Fundamentals
Return on Equity
-11.03%
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$75.13
▲(29.71% Upside)
Technical Analysis
Intellia Therapeutics
―
Arrowhead Pharmaceuticals
―
Bluebird Bio
―
Sangamo Biosciences
―
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+21.04%
reiterated a buy rating 4 months ago
Copying Anthony Butler's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +21.04% per trade.
---